Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

In a study of around 228,000 people in Sweden who had alcohol use disorder, researchers found that people who were taking a ...

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- The blockbuster GLP-1 drug semaglutide ( Ozempic, Wegovy) could curb drinking ...

The discovery could lead to a new treatment for millions of people with obesity and type 2 diabetes who do not respond well ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

This is just a glimpse of the GLP-1 insights available to CivicScience clients. Want to see the full picture? Let’s talk.

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

Pemvidutide is a promising GLP-1/glucagon dual receptor agonist that focuses on fundamental metabolic processes to stimulate ...